  announced that a number of pharmaceutical companies including GlaxoSmithKline and Roche have agreed to participate in the creation of a set of industry patient enrollment benchmarks based on real-world clinical performance data. Each of the initial sponsors will contribute their historical enrollment data, which will be anonymized, aggregated, and made available to all participants via DecisionView’s StudyOptimizer for use in benchmarking, planning and forecasting clinical trial enrollment. 

“There is a huge demand for clinical performance data to inform and calibrate clinical trial planning,” said Alex Lancksweert, Director of Performance & Supplier Governance at GlaxoSmithKline. “Unfortunately, current solutions are not integrated directly into our processes or tools, making it difficult to take advantage of them. We see a lot of value in leveraging the detailed enrollment performance data that already exists in StudyOptimizer to provide planning information at the point of need, in an accessible format.”


There is significant demand for trusted clinical trial performance data across a number of different clinical operations processes, including patient enrollment, site selection, budgeting, and clinical supply. In particular, more accurate patient enrollment benchmark data promises to significantly reduce clinical trial delays and cost overruns. Traditional sources for this type of benchmark information include company internal study data, third party data sets, and survey-based benchmarks. But capturing and maintaining this type of data over time can be challenging, for a number of reasons:

lack of data granularity (e.g. ability to segment the data by patient population, inclusion/exclusion criteria, etc,), 

lack of data breadth/scope/coverage across multiple therapeutic areas and geographic regions

no integration with planning processes and tools, 

Because of these challenges, a number of DecisionView’s customers asked the company to coordinate an effort to aggregate and share the clinical enrollment data that already exists in the StudyOptimizer product. 


In response, DecisionView has announced a new product called DecisionView Enrollment Benchmarks, a set of metrics based on real-world clinical performance data aggregated from DecisionView customers. In order to access the data set, customers must agree to contribute their enrollment data, which will be aggregated and anonymized to ensure the confidentiality of sponsor studies. The breadth and depth of studies in the Enrollment Benchmarks data set will grow as participating sponsors complete additional studies, and as new contributors add their portfolios of completed trial data.

The benefits of DecisionView’s approach to aggregating enrollment benchmarks include:

 – because the data is collected through StudyOptimizer and has been mapped to their data definitions, sponsors understand how it is defined and gathered

 – the rich set of clinical performance data informs and calibrates both initial clinical trial planning and trial rescue/recovery planning

 - provides planning information at the point of need, in an easily-accessible format 

- provides benchmark information where sponsors have little or no prior experience – new indications or new countries

- provides study teams, not just senior management, with a prospective capability to affect improved performance